Invocare share price wobbly following half-year results

Invocare Limited (ASX: IVC) announced its half-year results for 2020 this morning. How did it perform and are Invocare shares a good long-term buy?

| More on:
man looking at tablet with stock charts behind

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Invocare Limited (ASX: IVC) share price edged as much as 2% higher in early trade after the funeral home operator released its half-year results for FY2020. The Invocare share price has since dropped to $9.86 per share at the time of writing, down 1.40% for the day.

How did Invocare perform?

Notwithstanding the difficulties posed by COVID-19 restrictions on funeral attendances specifically, Invocare's performance was largely resilient in the circumstances. In particular, the government-imposed restrictions of funeral attendance numbers was cited as "the key driver in declining revenue".  

Invocare's revenue declined by 6.2% overall between the January and June period, operating earnings before interest, taxes, depreciation and amortisation (EBITDA) were down in the order of 22.7% and net profits after tax were down by as much as 143% compared to 2019 half-year levels.

Despite these underwhelming results, the company is seeing customer preferences return to pre-COVID trends since restrictions have eased, with higher attendances expected to drive earnings uplift for the second half of 2020.

The company will pay out to shareholders its previously deferred dividend of 23.5 cents, as well as a 5.5 cent interim dividend on 5 October.

In commenting on the results and Invocare's ability to respond to a challenging environment, CEO Martin Earp added: "Innovative new services, capital raising, debt refinancing, new operational procedures to safeguard the safety of our staff and our client families are all clear examples of a business that has responded in an agile manner to adjust to the challenges experienced due to COVID."

Is the Invocare share price in the buy zone?

As alluded to by this morning's media release, there are a couple of tailwinds benefitting Invocare's business.

Firstly, the strong performance of recently renovated funeral homes, which have outpaced un-renovated sites, is a positive indication that Invocare's 'Protect and Grow' strategy has been worthwhile. As part of the strategy, Invocare has given a facelift to dozens of its funeral homes as a means to adapt to changing societal attitudes and client needs.

On the strong trends of its renovated facilities, Invocare's CEO commented: "One of the key issues to arise from this pandemic has been the recognition by families of the important role of funeral services and this gives us confidence to continue upgrading our service offerings to ensure that we meet the changing needs of our client families into the future."

The other significant tailwind that I believe will benefit the company in the long-term is Australia's ageing population. Government figures from the Australian Institute of Health and Welfare  show that as of 2017, close to 4 million Aussies were 65 and over. With the largest market share of any national funeral operator, InvoCare's operations will be a beneficiary of this macro trend.

Foolish takeaway

Invocare's half-year results aren't anything to write home about, but I'm still a believer in the company to perform strongly in the medium to long-term. The company has a track record of paying out a nice yield of 4%, and Australia's ageing population and its continued investment in its funeral sites bodes well for Invocare moving forward.

At the time of writing, the Invocare share price remains 37% lower compared to its 52-week high of $15.79.

Motley Fool contributor Toby Thomas owns shares of InvoCare Limited. The Motley Fool Australia has recommended InvoCare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »